Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.
|
| Abstract |
Despite various applications of kinase inhibitors in oncology and inflammatory diseases, the emergence of resistance still remains the major barrier to achieve long-term remission in cancer treatment. With the aim of overcoming the resistance induced by type IIB BRaf V600E selective inhibitor vemurafenib, and further ameliorating the antiproliferative activity, a novel type IIA Pan-Raf inhibitors Ia-Io based on pyrrolo[2,3-d] pyrimidine scaffold were designed and evaluated in this work. Herein, we tried to improve the cellular potency of the target compounds by increasing their solubility. Among them, Il, with the solubility of 0.107 mg/mL, demonstrated favorable cellular activity against vemurafenib-resistant carcinoma cells including BRafWT phenotypic melanoma SK-MEL-2 and BRafV600E phenotypic colorectal cancer HT-29 cell lines. Based on the well solubility, Il exhibited good metabolic stability compared to sorafenib and showed favorable pharmacokinetic profiles in rats. As for the biological mechanism research, Il had the similar P-ERK kinase inhibitory activity in A375 and SK-Mel-2 cells as our previously lead P-2. Il may become a good candidate compound to overcome the resistance associated with vemurafenib.
|
|---|---|
| Authors | Lu Wang, Yanmin Zhang, Qing Zhang, Gaoyuan Zhu, Zhimin Zhang, Chunqi Duan, Tao Lu, Weifang Tang |
| Journal | European journal of medicinal chemistry (Eur J Med Chem) Vol. 163 Pg. 243-255 (Feb 01 2019) ISSN: 1768-3254 [Electronic] France |
| PMID | 30529543 (Publication Type: Journal Article) |
| Copyright | Copyright © 2018 Elsevier Masson SAS. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!